



**BlueCross
BlueShield**

Federal Employee Program

**MEKTOVI
PRIOR APPROVAL REQUEST**

Send completed form to:
Service Benefit Plan
Prior Approval
P.O. Box 52080 MC 139
Phoenix, AZ 85072-2080
Attn: Clinical Services
Fax: **1-877-378-4727**

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Patient Information (required)				Provider Information (required)		
Date:				Provider Name:		
Patient Name:				Specialty:		NPI:
Date of Birth:	Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female			Office Phone:		Office Fax:
Street Address:				Office Street Address:		
City:	State:	Zip:		City:	State:	Zip:
Patient ID:	R <div style="border: 1px solid black; width: 150px; height: 1.2em; display: inline-block;"></div>			Physician Signature:		
PHYSICIAN COMPLETES						

Mektovi (binimetinib)

****Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit**

NOTE: Form must be completed in its entirety for processing

Is this request for brand or generic? ☐ Brand ☐ Generic

1. Will the patient need more than 540 tablets every 90 days? ☐ Yes* ☐ No

****If YES***, please specify the requested quantity: _____ tablets per 90 days

2. What is the patient's diagnosis?

☐ Metastatic melanoma **OR** ☐ Unresectable melanoma

a. Does the patient have a documented BRAF V600E or BRAF V600K mutation as detected by an FDA-approved test? ☐ Yes ☐ No

☐ Metastatic non-small cell lung cancer

a. Does the patient have a documented BRAF V600E mutation as detected by an FDA-approved test? ☐ Yes ☐ No

3. Has the patient been on Mektovi continuously for the last **6 months, excluding samples**? ☐ Yes* ☐ No

****If YES***, has the patient experienced disease progression or unacceptable toxicity while on Mektovi? ☐ Yes ☐ No

4. Does the prescriber agree to monitor the patient for the following: cardiomyopathy, venous thromboembolism, ocular toxicities, interstitial lung disease (ILD), hepatotoxicity, rhabdomyolysis, hemorrhage, and embryo-fetal toxicity? ☐ Yes ☐ No

5. Will Mektovi be used in combination with Braftovi (encorafenib)? ☐ Yes ☐ No



**BlueCross
BlueShield**

Federal Employee Program.

MEKTOVI

PRIOR APPROVAL REQUEST

Send completed form to:
Service Benefit Plan
Prior Approval
P.O. Box 52080 MC 139
Phoenix, AZ 85072-2080
Attn. Clinical Services
Fax: **1-877-378-4727**

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug Prior Authorization requests securely online. Online submissions may receive instant responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to Caremark.com/ePA .
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727 . Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed. <u>Please only fax the completed form once as duplicate submissions may delay processing times.</u>

**faster...
easier...
better...**

Introducing ePA! Online Prior Authorizations in minutes through Caremark.com/ePA. Sign up today!

CVS/caremark 